Механизмы устойчивости опухолей к цисплатину
novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link
formation in a cisplatin-resistant, small-cell lung carcinoma cell
line. Int J Cancer 1993; 53: 110-7.
72. Guchelaar H-J, Timmer-Bosscha H, Dam-Meiring A, Uges DRA,
Oosterhuis JW, Vries EGE Mulder NH. Enhancement of cisplatin and
etoposide cytotoxicity after all-trans retinoic-acid-induced cellular
differentiation of a murine embryonal carcinoma cell line. Int J
Cancer 1993; 55: 442-7.
73. Seki S, Hongo A, Zhang B, Akiyama K, Sarker AH, Kudo T.
Inhibition of cisplatin-mediated DNA damage in vitro by
ribonucleotides. Jpn J Cancer Res 1993; 84: 462-7.
74. Parekh HK, Simpkins H. The differential expression of
citokeratin 18 in cisplatin-sensitive and -resistant human ovarian
adenocarcinoma cells and its association with drug sensitivity.
Cancer Res 1995; 55: 5203-6.
75. Mirakhur B, Parekh HK, Simpkins H. Expression of the cisplatin
resistance phenotype in a human ovarian carcinoma cell line
segregates with chromosomes 11 and 16. Cancer Res 1996; 56: 2256-
62.
76. Mueller H, Eppeberger U. The dual role of mutant p 53 protein in
chemosensitivity of human cancers. Anticancer Res 1996, 16 (6B): 3845-
8.
77. Kawasaki t, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi
T. Abrogation of apoptosis induced by DNA-damaging agents in human
bladder-cancer cell lines with p 21/WAF1/CIP1 and/or p 53 gene
alterations. Int J Cancer 1996, 68 (4): 501-5.
78. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T,
Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the
susceptibility of p 53 non-functional malignant glioma cells to
cisplatin-induced apoptosis. Oncogene 1996, 13 (6): 1279-85.
79. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced
apoptosis in melanoma cells is p 53 dependent. Melanoma Res 1998, 8
(1): 17-23.
80. Biagosklonny MV, El-Deiry WS. Acute overexpression of wt p 53
facilitates anticancer drug-induced death of cancer and normal cells.
Int J Cancer 1998, 75 (6): 933-940.
81. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R,
Goldginger N, Pei H, Prokocimer M, Rotter V. Mutant p 53 protein
interferes with p 53-independent apoptotic pathways. Oncogene 1998,
16 (25): 3269-77.
82. Vasey PA, Jones NA, Jenkins S, Dive C, Broun R. Cisplatin,
camptothecin, and taxol sensitivities of cells with p 53-associated
multidrug resistance. Mol Pharmacol 1996, 50 (6): 1536-40.
83. Vikhanskaya F, Clerico L, Valenti M, Stazione NS, Broggini M,
Parodi S, Russo P. Mechanism of resistance to cisplatin in a human
ovarian-carcinoma cell line selected for resistance to doxorubicin:
possible role of p 53. Int J Cancer 1997, 72 (1): 155-9.
84. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes
associated with formation of Pt-DNA adducts in human ovarian
carcinoma cells with different cisplatin sensitivity. Cytometry 1997,
27 (1): 54-64.
85. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p 53
induction by cisplatin and X-rays in a cisplatin-resistant ovarian
tumor cell line. Cancer Res 1998, 58 (4): 698-703.
86. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spreas
CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV.
Restoration of wild-type p 53 activity in p 53-null HL-60 cells
confers multidrug sensitivity. Clin Cancer Res 1998, 4 (5): 1315-22.
87. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou
G, Benard J. Cisplatin-induced apoptosis and p 53 gene status in a
cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer
1996, 86 (1): 67-74.
88. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A,
Barnett GH. Interleukin-1-beta-converting enzyme mediates cisplatin-
induced apoptosis in malignant glioma cells. Cancer Res 1995, 55
(24): 6166-71.
89. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Sire GE,
Arzani D, Stanzione S, Parodi S, D`Incalci M, Russo P, Broggini M.
DDP-induced cytotoxicity is not influenced by p 53 in nine human
ovarian cancer cell lines with different p 53 status. Br J Cancer
1997, 76 (4): 474-9.
90. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression
of p 53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular
germ cell tumor cell lines. Br J Cancer 1998, 77 (10): 1562-7.
91. Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of
expression of p 53 and the product of the bcl-2 in lines of gastric
cancer cells during cisplatin-induced apoptosis. Eur Surg Res 1997,
29 (5), 396-402.
92. Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI.
Characterisation of the p 53 status, BCL-2 expression and radiation
and platinum drug sensitivity of a panel of human ovarian cancer cell
lines. Int J Cancer 1998, 77 (6): 913-8.
93. Nakata B, Chung KH, Ogawa M, Yanagawa K, Muguruma K, Inoue T,
Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa. P 53 protein
overexpression as a predictor of the response to themotherapy in
gastric cancer. Surg Today 1998, 28 (6): 595-8.
94. Petty R, Evans A, Duncan I, Kurbacher C, Cree I. Drug resistance
in ovarian cancer – the role of p 53. Payhol Oncol Res 1998, 4 (2):
97-102.
95. Simonian PL, Grillot DA, Andrews DW, Leber B, Nunez G. Bax
homodimerization is not required for Bax to accelarate chemotherapy-
induced cell death. J Biol Chem 1996, 271 (50): 32073-7.
96. Liu JR, Fletcher B, Page C, Hu C, Nunez G Baker V. Bcl-xL is
expressed in ovarian carcinoma and modulates chemotherapy-induced
apoptosis. Gynecol Oncol 1998, 70 (3), 398-403.
97. Miyake H. Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto
H, Gohji K, Arakawa S, Kamidono S, Saya H. Overexpression of Bcl-2 in
bladder cancer inhibits apoptosis induced by cisplatin and adenoviral-
mediated p 53 gebe transfer. Oncogene 1998, 16 (7): 1933-43.
98. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xl
can confer a multidrug resistance phenotype. Blood 1995, 86 (5): 1903-
10.
99.Simonian PL, Grillot AM, Nunez G. Bcl-2 and Bcl-Xl can
differentially block chemotherapy induced cell death. Blood 1997, 90
(3): 1208-16.
100. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin-
and paclitaxel-induced apoptosis of ovarian carcinoma cells and the
relationship between bax and bak up-regulation and the functional
status of p 53. Mol Pharmacol 1998, 53 (3): 819-26.
101. Boersma AW, Nooter K, Burger h, Kortland CJ, Stoter G. Bax
upregulation is an early event in cisplatin-induced apoptosis in
human testicular germ-cell tumor cell line NT2, as quantitated by
flow cytometry. Cytometry 1997, 27 (3): 275-82.
102. Lee JU, Hosotani R, Wada H, Doi R, Kosiba T, Fujimoto K,
Miyamoto Y, Mori C, Nakamura N, Shiota K, Imamura M. Mechanism of
apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer
Res 1997, 17 (5A): 3445-50.
103. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl
GJ, Chaganti RS. Human male germ cell tumor resistance to cisplatin
is linked to TP53 gene mutation. Oncogene 1998, 16 (18): 2345-9.
104. Sakahura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S,
Tsujimoto H, Imanishi T, Ogaki M, Yamazaki J, Hagiwara A, Yamaguchi
T, Sawai K, Takahashi T. Overexpression of bax sensitizes breast
cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997, 27
(7): 676-9.
105. Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T,
Zushi S, Kitamura S, Ueyama H, Matsuzawa Y. Modulation of apoptosis
by endogenous Bcl-Xl expression in MKN-45 human gastric cancer cells.
Oncogene 1998, 17(20): 2585-91.
106. Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue
T, Matsuoka T, Onoda N, Kato Y, SowaM. Predictive value of Bcl-2 and
Bax protein expression for chemotherapeutic effect in gastric cancer.
Apilot study. Oncol 1998, 55(6): 543-7.
107. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao
T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S,
Saito H, Johnston PG. Biological markers as a predictor for response
and prognosis of unresectable gastric cancer patients treated with 5-
fluorouracil and cis-platinum. Clin Cancer Res 1998, 4 (6): 1469-74.
108. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr
DJ. The prognostic significance of bcl-2 and p 53 expression in
ovarian carcinoma. Cancer Res 1996, 56 (9): 2178-84.
109. Muguruma K, Nakata B, Hirakawa K, Yamashita Y, Onoda N, Inoue T,
Matsuoka T, Kato Y, Sowa. P 53 and Bax protein expression as
predictor of chemotherapeutic effect in gastric carcinoma. Gan To
Kagaku Ryoho 1998, 3: 400-3.
110. Ferguson AW, Flatow U, MacDonald NJ, Larminat F, Bohr VA,
Steeg PS. Increased sensitivity to cisplatin by nm23-transfected
tumor cell lines. Cancer Res 1996; 56: 2931-5.
111.Masumoto N, Nakaano S. Cell signalling and CDDP resistance. Gan
To Kagaku Ryoho 1997, 24(4): 424-30.
112. Demidova NS, Ilynskaya GV, Shiryaeva OA, Chernova OB, Goncharova
SA, Kopnin BP. Decreased sensitivity of multidrug-resistant tumor
cells to cisplatin is correlated with sorcin gene co-amplification.
Neoplasma 1995; 42: 195-201.
